





**Genomic Health INC**  
**Rank 12 of 70**

The relative strengths and weaknesses of Genomic Health INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Genomic Health INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 107% points. The greatest weakness of Genomic Health INC is the variable Selling and Marketing Expense, reducing the Economic Capital Ratio by 75% points.

The company's Economic Capital Ratio, given in the ranking table, is 234%, being 72% points above the market average of 162%.

<b>Input Variable</b>	<b>Value in 1000 USD</b>
Assets, Current	144,992
Assets, Non-Current	13,752
Cost of Goods and Services Sold	0
Depreciation, Depletion, Amortization	0
General and Administrative Expense	54,392
Goodwill Impairment Loss	0
Intangible Assets	0
Labor Expense	0
Liabilities, Current	29,832
Long Term Liabilities	0
Operating Costs and Expenses	0
Other Assets	0
Other Compr. Net Income	-3.0
Other Expenses	43,089
Other Liabilities	0
Other Net Income	64
Other Revenues	261,595
Property Plant and Equipment	18,290
Research And Development Expense	66,333
Selling and Marketing Expense	110,602

<b>Output Variable</b>	<b>Value in 1000 USD</b>
Assets	177,034
Liabilities	29,832
Expenses	274,416
Revenues	261,595
Stockholders Equity	147,202
Net Income	-12,757
Comprehensive Net Income	-12,760
BaseVar	371,472
ECR before LimitedLiability	194%
Economic Capital Ratio	234%